Dongzong Cardiovascular Bio-imaging Registry Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorJinling Hospital, China
About this trial
The DAILY project is a large-scale, multicenter, prospective initiative designed to establish a comprehensive bio-imaging database that integrates multidimensional data, including living environments, psychosocial and cognitive assessments, advanced lung and cardiovascular imaging, multi-omics profiles, clinical medication and surgical records, and health outcomes. Leveraging this extensive, multiscale dataset, the project aims to elucidate the intricate interplay between genetic biology and environmental factors in driving downstream biological alterations, thereby shaping lung and cardiovascular structural and functional phenotypes, and ultimately influencing the onset and progression of cardiovascular diseases (CVD). Through a systematic exploration and understanding of this complex network, the project seeks to identify critical intervention points and develop innovative strategies for the prevention and management of CVD.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Aged ≥18 years
Coronary CT angiography performed
Informed consent acquired
Disqualifiers
Unable to complete the follow-up
Serious chronic kidney disease (eGFR< 30 ml/min/1.73 m2)
Serious liver disease or dysfunction (chronic active hepatitis and cirrhosis, or aspartate aminotransferase (AST) or alanine transaminase (ALT) > 3 times the upper limit of normal)
Not appropriate to be tested due to birth planning, allergies, acute thyroid storm, etc.
Trial population
Consecutively enrolled individuals scheduled for coronary CTA, including those with known or suspected coronary artery disease (CAD) or individuals undergoing screening
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Major adverse cardiovascular events
Occurrence of major adverse cardiovascular events at prespecified follow-up ( once a year till the thirty year), defined as a composite of all-cause death, non-fatal myocardial infarction, unplanned revascularization , and hospitalization for unstable angina. Death cases consist of cardiovascular death, non-cardiovascular death, and undetermined cause of death.
Time frame
Once a year until the tenth yearSecondary outcomes
1
Invasive coronary angiography
Including invasive coronary angiography, diagnostic invasive coronary angiography with revascularization, and invasive coronary angiography without obstructive coronary disease (\> 70% or \>50% diameter stenosis)
Time frame
Once a year until the tenth year2
Coronary revascularization
Coronary artery bypass grafting, percutaneous coronary interventions
Time frame
Once a year until the tenth year3
Cardiovascular death, heart failure, atrial fibrillation, non-fatal MI, non-fatal stroke, unplanned revascularization, hospitalization for unstable angina
Cardiovascular death, heart failure, atrial fibrillation, non-fatal MI, non-fatal stroke, unplanned revascularization, hospitalization for unstable angina
Time frame
Once a year until the tenth year4
Coronary plaque progression, regression, formation
Changes in the degree of coronary artery stenosis or plaque volume, or coronary plaque formation, or the volume, characteristics, and composition of high-risk plaques will be observed in participants with serial coronary CTA
Time frame
Once every two years at least, until the tenth yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov